28.11.2008, Brussels

DG Competition reports that delaying tactics by originator pharmaceutical
companies cost society €3 billion.

The EGA and the BGPharmA welcome the findings of the preliminary report on the sector
inquiry, launched today in Brussels. This inquiry was initiated in January
2008 by Neelie Kroes, European Commissioner for Competition, in an attempt
to identify inefficiencies in the pharmaceutical market that create
obstacles to rapid access for consumers to affordable generic medicines
and to new innovative products.


Read the whole text here

For more information please visit:  http://europa.eu/rapid/pressReleasesAction.do?reference=IP/08/1829&format=HTML&aged=0&language=EN&guiLanguage=en

BGPharmA